Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting insulin analogs.

R H Rosskamp1, G Park

  • 1Department of Metabolism and Endocrinology, Hoechst Marion Roussel, Bridgewater, New Jersey 08807-0800, USA.

Diabetes Care
|March 31, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of organic loading rate on bioflocculant production derived from waste glycerin pitch and mixed microbial culture in single-step system.

Bioresource technology·2026
Same author

Digital quantum magnetism on a trapped-ion quantum computer.

Nature·2026
Same author

Effects of inclusion of black soldier fly larvae on growth performance, relative organ weight, and meat quality of broiler chickens.

Poultry science·2025
Same author

Bone regeneration at extraction sockets filled with leukocyte-platelet-rich fibrin: An experimental pre-clinical study.

Medicina oral, patologia oral y cirugia bucal·2022
Same author

Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19.

Journal of chemical information and modeling·2020
Same author

Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19.

ChemRxiv : the preprint server for chemistry·2020
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

New insulin formulations aim to provide 24-hour basal insulin coverage, reducing glucose variability and nocturnal hypoglycemia. These advancements in diabetes management offer improved physiological simulation for better glycemic control.

Area of Science:

  • Pharmacology and Endocrinology
  • Diabetes Mellitus Therapeutics

Background:

  • Current intermediate/long-acting insulin injections fail to achieve 24-hour basal insulinemia.
  • Existing insulin preparations exhibit high variability, pronounced peaks, and increase the risk of nocturnal hypoglycemia.
  • These limitations poorly mimic physiological insulin secretion patterns.

Purpose of the Study:

  • To evaluate novel insulin formulations designed for prolonged action and improved physiological profiles.
  • To assess the efficacy and safety of these new insulins in achieving sustained normoglycemia.

Main Methods:

  • Development of insulin analogs by shifting the isoelectric point (e.g., HOE 901).
  • Utilizing fatty acid acylation to enhance albumin binding and prolong insulin action.

Related Experiment Videos

  • Clinical trials comparing new formulations against existing insulins (e.g., NPH insulin).

    • Main Results:

    • HOE 901 demonstrated a constant, peakless profile over 24 hours in healthy volunteers.
    • Four-week trials showed HOE 901 achieved significantly lower fasting plasma glucose levels compared to NPH insulin.
    • Lower rates of nocturnal hypoglycemia were observed with the novel insulin formulation.

    Conclusions:

    • Modified insulin properties, such as altered isoelectric points and albumin binding, can prolong insulin action.
    • New insulin preparations show promise in reducing glucose variability and hypoglycemia.
    • Combination therapies with long- and short-acting insulins may be key to achieving sustained normoglycemia in diabetes.